| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5948856 | Atherosclerosis | 2012 | 6 Pages |
Abstract
⺠Diabetes was associated with a higher incidence of 2-fold increases in hs-cTnI levels. ⺠There was a marked suppression of the late elevation (>13 weeks) of high sensitivity Troponin I in patients treated with darapladib. ⺠This marked suppression was more apparent in patients that had Acute Coronary Syndromes (ACS) at the time of randomization to darapladib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Héctor M. GarcÃa-GarcÃa, Rohit M. Oemrawsingh, Salvatore Brugaletta, Pascal Vranckx, Jennifer Shannon, Richard Davies, Eric Boersma, Patrick W. Serruys,